Expansion leverages a custom module to help health systems identify patients eligible for lifesaving therapy ALISO VIEJO, Calif.–(BUSINESS WIRE)–#digitalhealth—egnite, Inc., a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom module designed to help physicians and health systems identify patients with atrial fibrillation (AF), deemed … [Read more…]

– Long-term follow-up data for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in advanced bladder cancer to be featured as oral presentation – – Updated Phase 1 data on first-in-class integrin beta-6 targeted antibody-drug conjugate (ADC) (SGN-B6A) to be presented – BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the … [Read more…]

Oral presentation on Phase 2 trial evaluating balstilimab/zalifrelimab plus standard of care in advanced sarcoma Poster discussion on Phase 1 trial investigating AGEN2373 monotherapy in advanced solid tumors LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the … [Read more…]

BENTONVILLE, Ark.–(BUSINESS WIRE)–Families in Oklahoma can now experience convenient access to healthcare with the opening of four new Walmart Health centers in the Oklahoma City-area. The openings mark Walmart Health’s expansion into the state, the third new state Walmart Health is entering in 2024, in addition to Missouri and Arizona, as well as deepening our … [Read more…]

Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASCO23–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the … [Read more…]

ROOT, Switzerland–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6. The LUNAR study … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present dose expansion data from the ongoing Phase 1/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell … [Read more…]

Former global business development leader at Airbnb, Kilroy will usher in the next phase of ŌURA’s business partnerships and enterprise offerings SAN FRANCISCO–(BUSINESS WIRE)–ŌURA, the company behind the smart ring that delivers personalized health data, insights, and daily guidance, today announced the addition of its first-ever Chief Commercial Officer, Dorothy Kilroy. Kilroy will lead the … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company earned a spot on Forbes’ 2023 “America’s Best Employers for Diversity” list. This is the fourth time that Philips has appeared in the ranking, which is limited to 500 organizations across the country and just 13 … [Read more…]

NEW YORK–(BUSINESS WIRE)–Acuamark Diagnostics has appointed Giulia Kennedy, Ph.D., formerly global chief scientific officer and chief medical officer of diagnostics company Veracyte, to its board of directors. Dr. Kennedy is a prolific research, product and clinical development executive with more than 20 years of experience propelling novel diagnostic technologies from early-phase research to commercialization and … [Read more…]